Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Diabetes

  Free Subscription


Articles published in Circulation

Retrieve available abstracts of 108 articles:
HTML format



Single Articles


    July 2020
  1. HAYNES N, Cooper LA, Albert MA
    At the Heart of the Matter: Unmasking and Addressing the Toll of COVID-19 on Diverse Populations.
    Circulation. 2020;142:105-107.
    PubMed    


    June 2020
  2. POTPARA TS, Lip GYH
    Combining Anticoagulant and Antiplatelet Therapies for Chronic Atherosclerotic Disease: A Focus on Diabetes Mellitus as a High-Risk Patient Group.
    Circulation. 2020;141:1855-1858.
    PubMed    


    April 2020
  3. HOYER FF, Zhang X, Coppin E, Vasamsetti SB, et al
    Bone Marrow Endothelial Cells Regulate Myelopoiesis in Diabetes.
    Circulation. 2020 Apr 22. doi: 10.1161/CIRCULATIONAHA.120.046038.
    PubMed     Abstract available


  4. GRANGER CB, Mahaffey KW
    Preventing Atrial Fibrillation With Treatments for Diabetes Mellitus.
    Circulation. 2020;141:1235-1237.
    PubMed    


  5. ARNOLD SV, Bhatt DL, Barsness GW, Beatty AL, et al
    Clinical Management of Stable Coronary Artery Disease in Patients With Type 2 Diabetes Mellitus: A Scientific Statement From the American Heart Association.
    Circulation. 2020 Apr 13:CIR0000000000000766. doi: 10.1161/CIR.0000000000000766.
    PubMed     Abstract available


  6. FRIED JA, Ramasubbu K, Bhatt R, Topkara VK, et al
    The Variety of Cardiovascular Presentations of COVID-19.
    Circulation. 2020 Apr 3. doi: 10.1161/CIRCULATIONAHA.120.047164.
    PubMed    


    March 2020
  7. SOUSA GR, Kosiborod M, Bluemke DA, Lipes MA, et al
    Cardiac Autoimmunity Is Associated With Subclinical Myocardial Dysfunction in Patients With Type 1 Diabetes Mellitus.
    Circulation. 2020;141:1107-1109.
    PubMed    


  8. BHATT DL, Eikelboom JW, Connolly SJ, Steg PG, et al
    The Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes and Cardiovascular Disease: Insights from the COMPASS Trial.
    Circulation. 2020 Mar 28. doi: 10.1161/CIRCULATIONAHA.120.046448.
    PubMed     Abstract available


  9. PANDEY A, Patel KV, Bahnson JL, Gaussoin SA, et al
    Association of Intensive Lifestyle Intervention, Fitness and Body Mass Index with Risk of Heart Failure in Overweight or Obese Adults with Type 2 Diabetes Mellitus: An Analysis from the Look AHEAD Trial.
    Circulation. 2020 Mar 5. doi: 10.1161/CIRCULATIONAHA.119.044865.
    PubMed     Abstract available


  10. TSUDA K
    Letter by Tsuda Regarding Article, "Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial".
    Circulation. 2020;141:e100-e101.
    PubMed    


    January 2020
  11. SHARMA A, Pagidipati NJ, Califf RM, McGuire DK, et al
    Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
    Circulation. 2020 Jan 29. doi: 10.1161/CIRCULATIONAHA.119.041022.
    PubMed     Abstract available


  12. BERGMARK BA, Bhatt DL, McGuire DK, Scirica BM, et al
    Response by Bergmark et al to Letter Regarding Article, "Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial".
    Circulation. 2020;141:e57-e58.
    PubMed    


  13. MORDI IR, Mohan M, Lang CC
    Letter by Mordi et al Regarding Article, "Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial".
    Circulation. 2020;141:e55-e56.
    PubMed    


  14. ZELNIKER TA, Bonaca MP, Furtado R, Mosenzon O, et al
    Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial.
    Circulation. 2020 Jan 27. doi: 10.1161/CIRCULATIONAHA.119.044183.
    PubMed     Abstract available


  15. GAN L, Xie D, Liu J, Lau WB, et al
    Small Extracellular Microvesicles Mediated Pathological Communications between Dysfunctional Adipocytes and Cardiomyocytes as a Novel Mechanisms Exacerbating Ischemia/Reperfusion Injury in Diabetic Mice.
    Circulation. 2020 Jan 10. doi: 10.1161/CIRCULATIONAHA.119.042640.
    PubMed     Abstract available


    December 2019
  16. BUTLER J, Packer M, Greene SJ, Fiuzat M, et al
    Heart Failure End Points in Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitors in Patients With Type 2 Diabetes Mellitus: A Critical Evaluation of Clinical and Regulatory Issues.
    Circulation. 2019;140:2108-2118.
    PubMed     Abstract available


  17. GRANDI SM, Smith GN, Platt RW
    The Relative Contribution of Pregnancy Complications to Cardiovascular Risk Prediction: Are We Getting It Wrong?
    Circulation. 2019;140:1965-1967.
    PubMed    


    November 2019
  18. PETRIE MC
    Sodium Glucose Cotransporter 2 Inhibitors: Searching for Mechanisms in the Wake of Large, Positive Cardiovascular Outcomes Trials.
    Circulation. 2019;140:1703-1705.
    PubMed    


  19. ARNOTT C, Neal B
    Do GLP-1 Receptor Agonists Care if You Have Heart Failure?
    Circulation. 2019;140:1623-1625.
    PubMed    


  20. CANNON CP, Perkovic V, Agarwal R, Baldassarre J, et al
    Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial.
    Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044359.
    PubMed     Abstract available


  21. MAZER CD, Hare GMT, Connelly PW, Gilbert RE, et al
    Effect of Empagliflozin on Erythropoietin Levels, Iron Stores and Red Blood Cell Morphology in Patients with Type 2 Diabetes and Coronary Artery Disease.
    Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044235.
    PubMed     Abstract available


    October 2019
  22. ELGHAZALY H, Hajiev S, Singh P
    Letter by Elghazaly et al Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus".
    Circulation. 2019;140:e738-e739.
    PubMed    


  23. KATO ET, Sabatine MS, Wiviott SD
    Response by Kato et al to Letter Regarding Article, "Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus".
    Circulation. 2019;140:e740-e741.
    PubMed    


  24. SATTAR N, Rawshani A, Franzen S
    Response by Sattar et al to Letters Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks".
    Circulation. 2019;140:e724-e725.
    PubMed    


  25. WANG J, Xu Y
    Letter by Wang and Xu Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks".
    Circulation. 2019;140:e722-e723.
    PubMed    


  26. WANG D, Chen T, Yang X
    Letter by Wang et al Regarding Article, "Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks".
    Circulation. 2019;140:e720-e721.
    PubMed    


  27. GODOY LC, Rao V, Farkouh ME
    Coronary Revascularization of Patients With Diabetes Mellitus in the Setting of Acute Coronary Syndromes.
    Circulation. 2019;140:1233-1235.
    PubMed    


  28. ZIMMET PZ, Rutherford JD
    Reflections on the Evolving Global Diabetes Epidemic: A Conversation With Paul Z. Zimmet, MBBS, MD, PhD.
    Circulation. 2019;140:1140-1144.
    PubMed    


  29. BARRETT TJ, Distel E, Murphy AJ, Hu J, et al
    Apolipoprotein AI) Promotes Atherosclerosis Regression in Diabetic Mice by Suppressing Myelopoiesis and Plaque Inflammation.
    Circulation. 2019;140:1170-1184.
    PubMed     Abstract available


  30. RADER DJ
    Enhancing Atherosclerosis Regression in Diabetic Mice Through Apo AI (Apolipoprotein AI).
    Circulation. 2019;140:1185-1187.
    PubMed    


  31. DIAZ R, Tajer C
    Current Status and Future Strategies for Cardiovascular Disease in Argentina.
    Circulation. 2019;140:1137-1139.
    PubMed    


    September 2019
  32. FUDIM M, White J, Pagidipati NJ, Lokhnygina Y, et al
    Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes With and Without Heart Failure and Heart Failure-Related Outcomes: Insights From the EXSCEL Trial.
    Circulation. 2019 Sep 23. doi: 10.1161/CIRCULATIONAHA.119.041659.
    PubMed     Abstract available



  33. Correction to: Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America.
    Circulation. 2019;140:e692.
    PubMed    


  34. NASSIF ME, Windsor S, Tang F, Khariton Y, et al
    Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
    Circulation. 2019 Sep 16. doi: 10.1161/CIRCULATIONAHA.119.042929.
    PubMed    


    August 2019
  35. BERG DD, Wiviott SD, Scirica BM, Gurmu Y, et al
    Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus.
    Circulation. 2019 Aug 31. doi: 10.1161/CIRCULATIONAHA.119.042685.
    PubMed    


  36. VERMA S, Mazer CD, Yan AT, Mason T, et al
    Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.
    Circulation. 2019 Aug 22. doi: 10.1161/CIRCULATIONAHA.119.042375.
    PubMed     Abstract available


  37. SANCHEZ EJ, Cefalu WT
    Know Diabetes by Heart.
    Circulation. 2019;140:526-528.
    PubMed    


  38. PACKER M
    Reconceptualization of the Molecular Mechanism by Which Sodium-Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Events.
    Circulation. 2019;140:443-445.
    PubMed    


    July 2019
  39. BERGMARK BA, Bhatt DL, McGuire DK, Cahn A, et al
    Metformin Use and Clinical Outcomes among Patients with Diabetes with or without Heart Failure or Kidney Dysfunction: Observations from the SAVOR-TIMI 53 Trial.
    Circulation. 2019 Jul 31. doi: 10.1161/CIRCULATIONAHA.119.040144.
    PubMed     Abstract available


  40. MORRIS DR, Sherliker P, Clack R, Preiss D, et al
    Opposite Associations of Aortic Aneurysm With Blood Glucose and With Diabetes Mellitus.
    Circulation. 2019;140:264-266.
    PubMed    


  41. MAHAFFEY KW, Jardine MJ, Bompoint S, Cannon CP, et al
    Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results from the Randomized CREDENCE Trial.
    Circulation. 2019 Jul 11. doi: 10.1161/CIRCULATIONAHA.119.042007.
    PubMed     Abstract available


    June 2019
  42. KRONLAGE M, Dewenter M, Grosso J, Fleming T, et al
    O-GlcNAcylation of Histone Deacetylase 4 Protects the Diabetic Heart from Failure.
    Circulation. 2019 Jun 14. doi: 10.1161/CIRCULATIONAHA.117.031942.
    PubMed     Abstract available


  43. ARNOLD SV, de Lemos JA, Rosenson RS, Ballantyne CM, et al
    Use of Guideline-Recommended Risk-Reduction Strategies Among Patients with Diabetes and Atherosclerotic Cardiovascular Disease: Insights from Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOUL
    Circulation. 2019 Jun 7. doi: 10.1161/CIRCULATIONAHA.119.041730.
    PubMed     Abstract available


  44. DUNLAY SM, Givertz MM, Aguilar D, Allen LA, et al
    Type 2 Diabetes Mellitus and Heart Failure: A Scientific Statement From the American Heart Association and the Heart Failure Society of America.
    Circulation. 2019 Jun 6:CIR0000000000000691. doi: 10.1161/CIR.0000000000000691.
    PubMed     Abstract available


    May 2019
  45. MANN JFE, Fonseca V, Mosenzon O, Raz I, et al
    Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial".
    Circulation. 2019;139:e1017-e1018.
    PubMed    


  46. XIE J, Jiang M, Li L
    Letter by Xie et al Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial".
    Circulation. 2019;139:e1015-e1016.
    PubMed    


  47. NYSTROM T, Sartipy U, Contardi A, Lind M, et al
    Glycated Hemoglobin A1c Levels in Type 1 Diabetes Mellitus and Outcomes After Myocardial Infarction.
    Circulation. 2019;139:2380-2382.
    PubMed    


    April 2019
  48. JAMERSON KA
    Should Certain Antihyperglycemic Medications Be Preferred Over Antihypertensive Medications for Blood Pressure Control in Special Populations With Diabetes Mellitus?
    Circulation. 2019;139:2110-2112.
    PubMed    


  49. WRIGHT AK, Kontopantelis E, Emsley R, Buchan IE, et al
    Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes: A Population-Based Cohort Study Assessing Sex Disparities.
    Circulation. 2019 Apr 15. doi: 10.1161/CIRCULATIONAHA.118.039100.
    PubMed     Abstract available


  50. SATTAR N, Rawshani A, Franzen S, Rawshani A, et al
    Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks Findings From the Swedish National Diabetes Registry.
    Circulation. 2019 Apr 8. doi: 10.1161/CIRCULATIONAHA.118.037885.
    PubMed    


  51. LOW WANG CC, Everett BM, Burman KD, Wilson PWF, et al
    Cardiovascular Safety Trials for All New Diabetes Mellitus Drugs?
    Circulation. 2019;139:1741-1743.
    PubMed    


    March 2019
  52. FURTADO RHM, Bonaca MP, Raz I, Zelniker TA, et al
    Dapagliflozin and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Prior Myocardial Infarction: A Sub-analysis From DECLARE TIMI-58 Trial.
    Circulation. 2019 Mar 18. doi: 10.1161/CIRCULATIONAHA.119.039996.
    PubMed     Abstract available


  53. KATO ET, Silverman MG, Mosenzon O, Zelniker TA, et al
    Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus.
    Circulation. 2019 Mar 18. doi: 10.1161/CIRCULATIONAHA.119.040130.
    PubMed     Abstract available


  54. FIGTREE GA, Radholm K, Barrett TD, Perkovic V, et al
    Effects of Canagliflozin on Heart Failure Outcomes Associated with Preserved and Reduced Ejection Fraction in Type 2 Diabetes: Results from the CANVAS Program.
    Circulation. 2019 Mar 17. doi: 10.1161/CIRCULATIONAHA.119.040057.
    PubMed     Abstract available


    February 2019
  55. RAWSHANI A, Rawshani A, Sattar N, Franzen S, et al
    Relative Prognostic Importance and Optimal Levels of Risk Factors for Mortality and Cardiovascular Outcomes in Type 1 Diabetes.
    Circulation. 2019 Feb 25. doi: 10.1161/CIRCULATIONAHA.118.037454.
    PubMed     Abstract available


  56. FERDINAND KC, Izzo JL, Lee J, Meng L, et al
    Antihyperglycemic and Blood Pressure Effects of Empagliflozin in African Americans with Type 2 Diabetes and Hypertension.
    Circulation. 2019 Feb 21. doi: 10.1161/CIRCULATIONAHA.118.036568.
    PubMed     Abstract available


  57. ZELNIKER TA, Wiviott SD, Raz I, Im K, et al
    Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Co-Transporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of
    Circulation. 2019 Feb 21. doi: 10.1161/CIRCULATIONAHA.118.038868.
    PubMed     Abstract available


  58. PETERS SAE, Muntner P, Woodward M
    Sex Differences in the Prevalence of, and Trends in, Cardiovascular Risk Factors, Treatment, and Control in the United States, 2001 to 2016.
    Circulation. 2019;139:1025-1035.
    PubMed     Abstract available


  59. KIDOKORO K, Cherney DZI, Bozovic A, Nagasu H, et al
    Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice using In Vivo Imaging.
    Circulation. 2019 Feb 18. doi: 10.1161/CIRCULATIONAHA.118.037418.
    PubMed     Abstract available


  60. PETRIE JR, Sattar N
    Excess Cardiovascular Risk in Type 1 Diabetes Mellitus.
    Circulation. 2019;139:744-747.
    PubMed    


    January 2019
  61. WU S, Lu Q, Ding Y, Wu Y, et al
    Hyperglycemia-Driven Inhibition of AMP-Activated Protein Kinase alpha2 Induces Diabetic Cardiomyopathy by Promoting Mitochondria-Associated Endoplasmic Reticulum Membranes in vivo.
    Circulation. 2019 Jan 16. doi: 10.1161/CIRCULATIONAHA.118.033552.
    PubMed     Abstract available


  62. FIGTREE GA, Radholm K, Neal B
    Response by Figtree et al to Letter Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)".
    Circulation. 2019;139:418-419.
    PubMed    


  63. KOH KK
    Letter by Koh Regarding Article, "Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)".
    Circulation. 2019;139:416-417.
    PubMed    


  64. ZANNAD F, Rossignol P
    Dipeptidyl Peptidase-4 Inhibitors and the Risk of Heart Failure.
    Circulation. 2019;139:362-365.
    PubMed    


  65. GREENE SJ, Butler J
    Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
    Circulation. 2019;139:152-154.
    PubMed    


    December 2018
  66. BJORNSTAD P, Schafer M, Truong U, Cree-Green M, et al
    Metformin Improves Insulin Sensitivity and Vascular Health in Youth With Type 1 Diabetes Mellitus.
    Circulation. 2018;138:2895-2907.
    PubMed     Abstract available


  67. MANN JFE, Fonseca V, Mosenzon O, Raz I, et al
    Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease.
    Circulation. 2018;138:2908-2918.
    PubMed     Abstract available


  68. VERMA S, Poulter NR, Bhatt DL, Bain SC, et al
    Effects of Liraglutide on Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus With or Without History of Myocardial Infarction or Stroke.
    Circulation. 2018;138:2884-2894.
    PubMed     Abstract available


    November 2018
  69. KARIO K, Okada K, Kato M, Nishizawa M, et al
    24-Hour Blood Pressure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Results from the Randomized, Placebo-Controlled SACRA Study.
    Circulation. 2018 Nov 29. doi: 10.1161/CIRCULATIONAHA.118.037076.
    PubMed     Abstract available


  70. SOUSA GR, Pober D, Galderisi A, Lv H, et al
    Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus: A DCCT/EDIC Cohort-Based Study.
    Circulation. 2018 Nov 26. doi: 10.1161/CIRCULATIONAHA.118.036068.
    PubMed     Abstract available


  71. MCGUIRE DK, Alexander JH, Johansen OE, Perkovic V, et al
    Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA.
    Circulation. 2018 Nov 11. doi: 10.1161/CIRCULATIONAHA.118.038352.
    PubMed     Abstract available


    October 2018
  72. DONZELLI A, Schivalocchi A, Giudicatti G
    Letter by Donzelli et al Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Effica
    Circulation. 2018;138:1912-1913.
    PubMed    


  73. KOH KK
    Letter by Koh Regarding Article, "Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus: Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy Internat
    Circulation. 2018;138:1914-1915.
    PubMed    


  74. INZUCCHI SE, Kosiborod M, Fitchett D, Wanner C, et al
    Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control.
    Circulation. 2018;138:1904-1907.
    PubMed    


  75. KHERA A, Budoff MJ, O'Donnell CJ, Ayers CA, et al
    Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) Coronary Calcium Atherosclerotic Cardiovascular Disease Risk Calculator.
    Circulation. 2018;138:1819-1827.
    PubMed     Abstract available


  76. VERMA S, Leiter LA, Mazer CD, Bain SC, et al
    Liraglutide Reduces Cardiovascular Events and Mortality in Type 2 Diabetes Mellitus Independently of Baseline Low-Density Lipoprotein Cholesterol Levels and Statin Use.
    Circulation. 2018;138:1605-1607.
    PubMed    


  77. CLAGGETT B, Lachin JM, Hantel S, Fitchett D, et al
    Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease.
    Circulation. 2018;138:1599-1601.
    PubMed    


    September 2018
  78. MADIAS JE
    Letter by Madias Regarding Article, "Long-Term Outcomes in Patients With Type 2 Myocardial Infarction and Myocardial Injury".
    Circulation. 2018;138:1176-1177.
    PubMed    


  79. CHAPMAN AR, Mills NL
    Response To Letter Regarding Article "Long-Term Outcomes in Patients With Type 2 Myocardial Infarction and Myocardial Injury".
    Circulation. 2018;138:1178.
    PubMed    


    August 2018
  80. TAMPAKIS A, Tampaki EC, Gurke L
    Letter by Tampakis et al Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
    Circulation. 2018;138:848-849.
    PubMed    


  81. WANNER C, von Eynatten M, Zinman B
    Response by Wanner et al to Letters Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
    Circulation. 2018;138:850-851.
    PubMed    


  82. KOH KK
    Letter by Koh Regarding Article, "Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease".
    Circulation. 2018;138:846-847.
    PubMed    


    July 2018
  83. SATTAR N, McGuire DK
    Pathways to Cardiorenal Complications in Type 2 Diabetes Mellitus: A Need to Rethink.
    Circulation. 2018;138:7-9.
    PubMed    


    June 2018
  84. MCALLISTER DA, Read S, Kerssens J, Livingstone S, et al
    Incidence of Hospitalisation for Heart Failure and Case-Fatality Among 3.25 Million People with and without Diabetes.
    Circulation. 2018 Jun 27. pii: CIRCULATIONAHA.118.034986.
    PubMed     Abstract available


  85. YOUNG LH, Viscoli CM, Schwartz GG, Inzucchi SE, et al
    Heart Failure After Ischemic Stroke or TIA in Insulin-Resistant Patients Without Diabetes Treated with Pioglitazone.
    Circulation. 2018 Jun 22. pii: CIRCULATIONAHA.118.034763.
    PubMed     Abstract available


    May 2018
  86. VERMA S, Bhatt DL, Bain SC, Buse JB, et al
    Effect of Liraglutide on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Polyvascular Disease: Results of the LEADER Trial.
    Circulation. 2018;137:2179-2183.
    PubMed    


  87. PACKER M
    Response by Packer to Letter Regarding Article, "Activation and Inhibition of Sodium-Hydrogen Exchange Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure".
    Circulation. 2018;137:1981-1982.
    PubMed    


  88. GAZMURI RJ, Karmazyn M
    Letter by Gazmuri and Karmazyn Regarding Article, "Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure".
    Circulation. 2018;137:1979-1980.
    PubMed    


    April 2018
  89. HU L, Qi Z, Zhang S, Luo X, et al
    Response by Hu et al to Letters Regarding Article, "Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus".
    Circulation. 2018;137:1877-1878.
    PubMed    


  90. GONG L, Li J, Yang G
    Letter by Gong et al Regarding Article, "Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus".
    Circulation. 2018;137:1875-1876.
    PubMed    


  91. JIN-SHAN H, Xue-Bin L
    Letter by Jin-shan and Xue-bin Regarding Article, "Platelets Express Activated P2Y12 Receptor in Patients With Diabetes Mellitus".
    Circulation. 2018;137:1874.
    PubMed    


    March 2018
  92. RADHOLM K, Figtree G, Perkovic V, Solomon SD, et al
    Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Circulation. 2018 Mar 11. pii: CIRCULATIONAHA.118.034222.
    PubMed     Abstract available


  93. VIJAYAKUMAR S, Vaduganathan M, Butler J
    Glucose-Lowering Therapies and Heart Failure in Type 2 Diabetes Mellitus: Mechanistic Links, Clinical Data, and Future Directions.
    Circulation. 2018;137:1060-1073.
    PubMed     Abstract available


    January 2018
  94. IANIRO G, Cammarota G, Gasbarrini A
    Letter by Ianiro et al Regarding Article, "Effect of Long-Term Metformin and Lifestyle in the Diabetes Prevention Program and Its Outcome Study on Coronary Artery Calcium".
    Circulation. 2018;137:213-214.
    PubMed    


  95. PLUTZKY J, Bakris G
    Sodium/Glucose Cotransporter 2 Inhibitors in Patients With Diabetes Mellitus and Chronic Kidney Disease: Turning the Page.
    Circulation. 2018;137:130-133.
    PubMed    


    December 2017
  96. GIUGLIANO RP, Cannon CP, Blazing MA, Nicolau JC, et al
    Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With vs. Without Diabetes: Results from IMPROVE-IT.
    Circulation. 2017 Dec 20. pii: CIRCULATIONAHA.117.030950.
    PubMed     Abstract available


    November 2017
  97. VERMA S, Mazer CD, Al-Omran M, Inzucchi SE, et al
    Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME.
    Circulation. 2017 Nov 13. pii: CIRCULATIONAHA.117.032031.
    PubMed     Abstract available


    October 2017
  98. LYTVYN Y, Bjornstad P, Udell JA, Lovshin JA, et al
    Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
    Circulation. 2017;136:1643-1658.
    PubMed     Abstract available


  99. YOUNG LH, Viscoli CM, Inzucchi SE, Kernan WN, et al
    Response by Young et al to Letters Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
    Circulation. 2017;136:1567-1568.
    PubMed    


  100. JIN-SHAN H, Xue-Bin L
    Letter by Jin-Shan and Xue-Bin Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
    Circulation. 2017;136:1565-1566.
    PubMed    


  101. MUSSO G, Cassader M, Gambino R
    Letter by Musso et al Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus".
    Circulation. 2017;136:1563-1564.
    PubMed    


  102. WOLSK E, Claggett B, Diaz R, Dickstein K, et al
    Increases in Natriuretic Peptides Precede Heart Failure Hospitalization in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
    Circulation. 2017;136:1560-1562.
    PubMed    


  103. PACKER M
    Activation and Inhibition of Sodium-Hydrogen Exchanger Is a Mechanism That Links the Pathophysiology and Treatment of Diabetes Mellitus With That of Heart Failure.
    Circulation. 2017;136:1548-1559.
    PubMed     Abstract available


  104. BUTLER J, Anker SD
    The Ethics of Conducting Clinical Trials With Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: Is Placebo Assignment Justified in Patients With Comorbid Diabetes Mellitus and Heart Failure?
    Circulation. 2017;136:1459-1461.
    PubMed    


    September 2017
  105. WILSON PWF, Gagnon D
    Diabetes Mellitus and Control of Cardiovascular Disease Risk Factors: A Challenge to Improve Usual Care.
    Circulation. 2017;136:1204-1206.
    PubMed    


  106. STRIEPE K, Jumar A, Ott C, Karg MV, et al
    Effects of the Selective Sodium-Glucose Cotransporter 2 Inhibitor Empagliflozin on Vascular Function and Central Hemodynamics in Patients With Type 2 Diabetes Mellitus.
    Circulation. 2017;136:1167-1169.
    PubMed    


  107. WANNER C, Lachin JM, Inzucchi SE, Fitchett D, et al
    Empagliflozin and Clinical Outcomes in Patients with Type 2 Diabetes, Established Cardiovascular Disease and Chronic Kidney Disease.
    Circulation. 2017 Sep 13. pii: CIRCULATIONAHA.117.028268.
    PubMed     Abstract available


    August 2017
  108. NAUCK MA, Meier JJ, Cavender MA, Abd El Aziz M, et al
    Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
    Circulation. 2017;136:849-870.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: